Benign Prostatic Hyperplasia Treatment Market Share, Trends, Scope, Opportunities and Competitive Outlook by 2025
According to IMARC Group’s new report, titled “Benign Prostatic Hyperplasia Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025”, the global benign prostatic hyperplasia treatment market grew at a CAGR of 8% during 2014-2019. Looking forward, IMARC Group expects the global market to continue its moderate growth during the next five years.
Benign prostatic hyperplasia (BPH) refers to non-cancerous growth of the prostate gland that causes urethra blockage. This disorder generally results in the retention of urine, formation of bladder stones, incontinence due to overfilling, increased sensitivity of the bladder, and urinary tract infections. Some commonly used treatment methods for BPH include prescription drugs, mono drug and combination therapy, Phyto-therapies, and minimally-invasive (MI) and invasive surgeries. Resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants are some of the standard instruments used in BPH treatment surgeries.
Request for a free sample copy of this report: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market/requestsample
The rising prevalence of urological disorders across the globe, coupled with the growing geriatric population, is currently driving the market growth. Furthermore, the increasing consumer awareness towards the availability of efficient and minimally-invasive treatment procedures for BPH is also propelling the market. Moreover, various advancements in the medical sector have led to the development of transurethral resection of the prostate (TURP) as an efficient treatment technique. TURP is an endoscopic electrosurgical procedure that removes a portion of the prostate gland to reduce the obstruction caused by abnormal growth. In addition to this, the rising healthcare expenditures and improving healthcare infrastructures will continue to drive the market growth in the coming years.
Market Overview:
Breakup by Treatment:
• Drug Class
o Alpha-Blockers
o 5-Alpha-reductase Inhibitors (5-ARIs)
o Phosphodiesterase-5 Enzyme Inhibitors
o Others
• Minimally Invasive Surgeries
o Transurethral Resection of the Prostate (TURP)
o Transurethral Incision of the Prostate (TUIP)
o Transurethral Microwave Thermotherapy (TUMT)
o Robotic Surgeries
o Prostatic Urethral Lifts
o Others
• Laser Therapy
• Others
Breakup by Region:
• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa
Explore full report with table of contents: https://www.imarcgroup.com/benign-prostatic-hyperplasia-treatment-market
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (AbbVie Inc.), Asahi Kasei Corporation, Astellas Pharma Inc., Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG), Boston Scientific Corporation, GlaxoSmithKline Plc, Pfizer Inc., Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
Browse Related Reports:
Cystic Fibrosis Therapeutics Market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
Comments
Post a Comment